PHGE | tickerfilter.com

Fundamental analysis

19%

Profitability 25%

Dept financing 16%

Liquidity 15%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-13.36%

1 Month

-26.27%

3 Months

-37.20%

6 Months

-49.06%

1 Year

28.32%

2 Year

70.94%

Key data

Stock price

$0.49

P/E Ratio

0.00

DAY RANGE

$0.48 - $0.57

EPS

-$1.84

52 WEEK RANGE

$0.13 - $1.62

52 WEEK CHANGE

$40.86

MARKET CAP

13.271 M

YIELD

N/A

SHARES OUTSTANDING

178.958 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.88

PUBLIC FLOAT

AVERAGE 10 VOLUME

$219,998

AVERAGE 30 VOLUME

$117,397

Company detail

CEO: Jonathan E. Solomon
Region: US
Website: biomx.com
Employees: 120
IPO year: 2019

Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

BiomX Inc. develops products using natural and engineered phage technologies to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC) The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S.Aureus), a bacteria associated

PHGE - BiomX Inc.